Aarey Drugs & Pharmaceuticals Q2 Results 2026: PAT ₹1 Cr +34%
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹89Cr
- +5.3% YoY
- +98.6% QoQ
- Net profit
- ₹1Cr
- +34.3% YoY
- +34.3% QoQ
- Margin
- 2.4%
- −0.7 pp YoY
- −0.6 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Aarey Drugs & Pharmaceuticals Ltd Q2 FY27 key numbers
- Revenue
- Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs.
As stated in Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 results statement · published 15 Nov 2026. Reported figures, not investment advice.
Based on Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs. EBITDA (Profit Before Exceptional Items and Tax + Depreciation + Finance Cost):.
From Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.
How did Aarey Drugs & Pharmaceuticals' revenue grow in the September 2026 quarter?
What happened to Aarey Drugs & Pharmaceuticals' margins in Q2 FY27?
EBITDA (Profit Before Exceptional Items and Tax + Depreciation + Finance Cost):
Locked: what Aarey Drugs & Pharmaceuticals Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Aarey Drugs & Pharmaceuticals planning?
- The company purchased fixed assets during the reporting period; however, these assets are not yet ready for their intended use as of period end (Sep 30, 2026) - no depreciation charged yet. Depreciation to commence once assets are fully installed and commissioned (Page 8, 4).
- Capital work-in-progress as of Sep 30, 2026 is ₹235.70 lakhs, decreased from ₹811.58 lakhs as of March 31, 2026 (Page 5).
- Funds raised through preferential issue of convertible warrants (₹3190 lakhs) are proposed to be used partly for augmentation of funding needs, repayment/presentment of liabilities/debts, investment in technology or general corporate purposes to enhance business (Page 15).
- As of Sep 30, 2026, ₹900 lakhs of funds from warrants remain unutilized and are pending utilization for stated objects (Page 15).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Aarey Drugs & Pharmaceuticals raising money or cutting debt?
The presentation mentions fundraising through the issuance of Convertible Warrants on a preferential…
Locked: what Aarey Drugs & Pharmaceuticals Ltd said on fundraising
Also locked on this page: margins, order book
Free account, 30 seconds. No card needed.
How big is Aarey Drugs & Pharmaceuticals' order book?
See what Aarey Drugs & Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Aarey Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit
Aarey Drugs & Pharmaceuticals Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 89 | 84 | +5.3% | 45 | +98.6% |
| Operating profit (EBITDA) | 2 | 3 | -18.9% | 1 | +60.9% |
| Operating margin | 2.4% | 3.1% | -0.7 pp | 3% | -0.6 pp |
| Profit before tax | 2 | 1 | +12.2% | 1 | +219.2% |
| Net profit (PAT) | 1 | 1 | +34.3% | 1 | +34.3% |
| EPS (₹) | 0.43 | 0.72 | -40.3% | 0.36 | +19.4% |
Source: Aarey Drugs & Pharmaceuticals Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹89 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
- Alpa Laboratorie (Q2 FY27)
Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aarey Drugs & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aarey Drugs & Pharmaceuticals Ltd Q2 FY27 results?
Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs. EBITDA (Profit Before Exceptional Items and Tax + Depreciation + Finance Cost):.
What is Aarey Drugs & Pharmaceuticals Ltd share price analysis?
Aarey Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 88.0 with a market cap of ₹367 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarey Drugs & Pharmaceuticals Ltd planning capital expenditure?
The company purchased fixed assets during the reporting period; however, these assets are not yet ready for their intended use as of period end (Sep 30, 2026) - no depreciation charged yet.
Keep Aarey Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
